Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amidst fluctuating market conditions.\n\nTop 10 High Growth Tech Companies In The United States\nName\t\tRevenue Growth\tEarnings Growth\tGrowth Rating\nSuper Micro Computer\t20.44%\t29.79%\t★★★★★★\nTG Therapeutics\t26.18%\t37.61%\t★★★★★★\nAlkami Technology\t20.46%\t85.16%\t★★★★★★\nTravere Therapeutics\t28.43%\t65.01%\t★★★★★★\nClene\t60.86%\t63.07%\t★★★★★★\nAVITA Medical\t27.91%\t55.77%\t★★★★★★\nTKO Group Holdings\t22.48%\t25.17%\t★★★★★★\nAlnylam Pharmaceuticals\t22.69%\t58.49%\t★★★★★★\nLumentum Holdings\t21.55%\t119.67%\t★★★★★★\nAscendis Pharma\t32.36%\t59.79%\t★★★★★★\nLet's uncover some gems from our specialized screener.\n\nSoleno Therapeutics (NasdaqCM:SLNO)\nSimply Wall St Growth Rating: ★★★★★☆\nOverview: Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics for treating rare diseases, with a market cap of $3.30 billion.\nOperations: Soleno Therapeutics focuses on developing and commercializing therapeutics for rare diseases. The company is in the clinical stage, indicating it is still in the process of bringing its products to market.\n\nSoleno Therapeutics recently celebrated a significant milestone with the FDA's approval of VYKAT XR for treating Prader-Willi syndrome, an achievement reflecting its innovative edge in specialized pharmaceuticals. Despite a challenging financial backdrop marked by a substantial net loss increase to $175.85 million from the previous year and ongoing shareholder dilution, Soleno's strategic filings and robust clinical program underscore its commitment to growth and patient support. The company's revenue is projected to surge by 50.1% annually, outpacing the broader U.S. market forecast of 8.3%, positioning it as a potentially transformative player in biotech, pending its anticipated profitability within three years.\n\nVerra Mobility (NasdaqCM:VRRM)\nSimply Wall St Growth Rating: ★★★★☆☆\nOverview: Verra Mobility Corporation provides smart mobility technology solutions and services across the United States, Australia, Europe, and Canada, with a market cap of $3.22 billion.\nOperations: The company generates revenue through three main segments: Commercial Services ($407.68 million), Government Solutions ($390.90 million), and Parking Solutions ($80.62 million).\n\nVerra Mobility, with a focus on fleet management and tolling solutions, recently partnered with Verizon Connect, enhancing its service offerings through integrated vehicle software solutions. This collaboration is expected to streamline operations for fleet managers by leveraging real-time data analytics. Despite facing challenges such as a significant net loss of $66.66 million in the last quarter of 2024 and ongoing high debt levels, Verra Mobility's strategic partnerships and innovative services are pivotal in maintaining its competitive edge in the tech-driven transportation sector. The company also repurchased shares worth $177.03 million last year, signaling confidence in its financial strategy despite the setbacks.

High Growth Tech Stocks To Watch In The US April 2025

The article highlights top 10 high growth tech companies in the US, focusing on their revenue growth, earnings growth, and market capitalization. Despite a challenging market, these companies are expected to demonstrate strong innovation potential and resilience. Notable companies include Soleno Therapeutics and Verra Mobility, both of which have seen significant milestones and strategic moves.